Floatz logo

Inno-206

Non-eligible for Autologous Stem Cell Transplantation (ASCT)

PETHEMA FoundationActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Non-eligible for Autologous Stem Cell Transplantation (ASCT) cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
PETHEMA Foundation
D
Cyclophosphamide
PETHEMA Foundation
D
DARATUMUMAB
PETHEMA Foundation
D
FILGRASTIM
PETHEMA Foundation
D
PREDNISONE TABLETS
PETHEMA Foundation
D
Bortezomib
PETHEMA Foundation
D
DEXAMETHASONE
PETHEMA Foundation
D

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →